Enzymes II Flashcards

1
Q

1) What is the difference between competitive and non-competitive enzyme inhibitors?

A
  • Competitive: block the enzyme active site so substrate cannot bind (e.g. malonate inhibition of succinate dehydrogenase)
  • Non-competitive: interferes with the catalytic mechanism in some other way
    > reversible: inhibition of Mg2+, requiring an enzyme by addition of chelator
    > irreversible: organophosphorous inhibition of cholinesterase
    [some enzyme can display multiple properties]
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

2) Define the term allosteric binding

A

Binding to another site of the enzyme (not the active site) in order to inhibit it
- produces inactive enzyme or enzyme-substrate complexes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

3) State one way in which competitive inhibitors can be overcome

A

Increasing substrate concentration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

4) What is the effect of competitive and non-competitive enzyme inhibitors on enzyme kinetic parameters (Vmax and Km)?

A

Competitive: Increase Km and same Vmax
- increased gradient of slope on LWB plot
Non-competitive: Same Km, lower Vmax
- decreased gradient of slope of LWB plot

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

5) What is ACE (angiotensin converting enzyme) involved in and what are risks associated with high levels of ACE activity?

A
  • involved in angiotensin production
  • converts angiotensin I to angiotensin II which leads to peripheral vasoconstriction, increasing blood pressure
  • if levels of A-II are high, this increases the risk of heart failure
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

6) How do ACE inhibitors treat heart failure?

A
  • inhibit formation of angiotensin II (by inhibiting ACE) and so reduces peripheral vasoconstriction so blood pressure decreases and there is a lower risk of heart failure
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

7) Describe the action of Acetylcholine esterase inhibitor when reversible

A
  • AChE-I binds to active enzyme
  • EI (enzyme-inhibitor) complex formed
  • groups on enzyme are transferred (deactivation)
  • there is a slow hydrolysis of the inactive enzyme, as it reverts back to its active form
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

8) Describe the action of Acetylcholine esterase inhibitor when irreversible

A
  • AChE-I binds to active enzyme
  • EI (enzyme-inhibitor) complex formed
  • Enzyme is phosphorylated, no spontaneous hydrolysis occurs -> irreversible deactivation of enzyme
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

9) Describe how the addition of a cure can reactivate this enzyme

A
  • ‘Cure’ molecule interacts with enzyme, is more attractive than the inhibitor
  • Allows enzyme to be reactivated as a phosphate group is transferred back and active enzyme is reformed
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

10) State 3 ways of metabolic regulation of enzyme activity

A
  • Allosteric binding sites (+ or - effectors)
  • covalent modification by other enzymes -> phosphorylation by kinases or dephosphorylation by phosphorylases
  • induction or repression of enzyme synthesis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

11) What curve do allosteric enzymes present?

A
  • sigmoidal curve
  • this shows low enzyme activity at low substrate concentration and an immediate, rapid increase in enzyme activity to Vmax, as [S] increases
  • since this does not fit the michaelis menton equation, K0.5 is used instead of Km
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

12) What is the difference between a positive and negative allosteric modulator and how does the MM plot change?

A

+ve: activator - lowers [S] required for Vmax
curve is above normal sigmoid
allows substrate to bind (changes enzyme shape to increase efficacy)
-ve: inhibitor - higher [S] needed for Vmax
curve is below normal sigmoid
prevents substrate from binding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

13) Define the two types of allosteric enzyme

A

1) homotrophic allosteric : multi-subunit enzymes, same binding site on each subunit functions as active and regulatory site
- the substrate/other molecule can be the effector
- binding of one substrate alters enzyme conformation and enhances binding of subsequent substrates
2) heterotrophic allosteric : the substrate is not the effector - a different molecule will bind to the regulatory site, the substrate can only bind at ONE site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

14) Give 2 examples of positive allosteric effectors and negative allosteric effectors

A
  • Positive: Phosphoenolpyruvate (PEP) and F1,6BP on pyruvate kinase
  • Negative: ATP and citrate on phosphofructokinase (while AMP is positive)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

15) Define covalent modification

A

Typically the addition or removal of phosphate from serine/threonin/tyrosine/histadine residues
- phosphorylation increases the activity of glycogen phosphorylase (degrades glycogen) and decreases the activity of glycogen synthase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

16) What are the potential effects of protein phosphorylation (3) and give 4 examples

A
  • Increase in activity, decrease in activity, catalysis of a different reaction
  • adenylylation - tyrosine residues
  • uridylylation - tyrosine residues
  • ADP-ribosylation - arginine, glutamine residues
  • Methylation - glutamate residues, can alter gene expression
17
Q

17) Define proteolytic activation

A
  • Some enzymes are synthesised as larger, inactive precursor forms that are called proenzymes or zymogens
  • activation involves the irreversible hydrolysis of one or more peptide bonds to produce an active form